CN104082742A - Functional food for adjusting blood glucose balance - Google Patents
Functional food for adjusting blood glucose balance Download PDFInfo
- Publication number
- CN104082742A CN104082742A CN201410320488.6A CN201410320488A CN104082742A CN 104082742 A CN104082742 A CN 104082742A CN 201410320488 A CN201410320488 A CN 201410320488A CN 104082742 A CN104082742 A CN 104082742A
- Authority
- CN
- China
- Prior art keywords
- functional food
- parts
- vitamin
- blood glucose
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 84
- 239000008280 blood Substances 0.000 title claims abstract description 84
- 239000008103 glucose Substances 0.000 title claims abstract description 65
- 235000013376 functional food Nutrition 0.000 title claims abstract description 63
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 57
- 239000002994 raw material Substances 0.000 claims abstract description 47
- 239000000284 extract Substances 0.000 claims abstract description 40
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 30
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 20
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 20
- 235000021511 Cinnamomum cassia Nutrition 0.000 claims abstract description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 15
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 15
- 229940046009 vitamin E Drugs 0.000 claims abstract description 15
- 239000011709 vitamin E Substances 0.000 claims abstract description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 15
- 230000003750 conditioning effect Effects 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 9
- 230000000474 nursing effect Effects 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 19
- 238000002474 experimental method Methods 0.000 abstract description 17
- 230000006870 function Effects 0.000 abstract description 17
- 230000003914 insulin secretion Effects 0.000 abstract description 9
- 230000001603 reducing effect Effects 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 36
- 235000000346 sugar Nutrition 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 206010012601 diabetes mellitus Diseases 0.000 description 27
- 238000000034 method Methods 0.000 description 16
- 229930003231 vitamin Natural products 0.000 description 16
- 235000013343 vitamin Nutrition 0.000 description 16
- 239000011782 vitamin Substances 0.000 description 16
- 229940088594 vitamin Drugs 0.000 description 16
- 150000003722 vitamin derivatives Chemical class 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000007689 inspection Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 10
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000012449 Kunming mouse Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 231100000027 toxicology Toxicity 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000013118 diabetic mouse model Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- YMCZETULMSWVBI-UHFFFAOYSA-N 2-(4-chlorophenoxy)acetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine Chemical compound CN(C)C(=N)N=C(N)N.OC(=O)COC1=CC=C(Cl)C=C1 YMCZETULMSWVBI-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011697 diabetes animal model Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a functional food for adjusting blood glucose balance. The functional food is prepared from the following raw materials in parts by mass: 30-50 parts of mulberry leaf extract, 30-50 parts of cinnamomum cassia extract, 5-10 parts of vitamin C and 5-10 parts of vitamin E. Proven by experiments, not only do the raw materials in the function food have respective functions, after the raw materials are mixed together to prepare the functional food, but also the functional food is capable of adjusting the pancreatic islet function well, assisting insulin secretion in a human body to achieve a balance, adjusting glucose metabolism, also reducing blood fat at the same time and preventing blood vessels from atherosclerosis, so that the functions of adjusting blood glucose balance and preventing complications can be achieved well.
Description
Technical field
The present invention relates to field of functional food, particularly a kind of functional food of nursing one's health blood glucose balance.
Background technology
Diabetes are a kind of common diseases, are after tumour, cardiovascular and cerebrovascular disease, to come the 3rd, one of chronic disease of serious harm human health.Its impact comprises long-term damage, dysfunction and the exhaustion of each organ.Frequently, whether so not serious diabetic symptom is; But long-term hyperglycemia causes cardiovascular disease, retinopathy (ablepsia, blind), ephrosis (kidney failure) and ulcer of foot, amputation etc.The fast-descending of cognitive function and other cerebral functions or tissue damage are often by diabetes-induced or concurrent.
Diabetes are a kind of a series of carbohydrates, lipid, protein metabolism derangement syndromes that cause because of body hypoinsulinism or insulin resistance etc.In recent years, the illness rate of China's diabetes increases sharply.The illness rate of whole nation generaI investigation diabetes in 1980 is that 0.67%, 1994 year diabetes prevalence rises to 2.51%.2007-2008, China has carried out the extensive epidemiology survey of diabetes.Result of study shows, the illness rate of national diabetes has reached 9.7%, and the illness rate of prediabetes is up to 15.5%.This means, China has become the country that global diabetic is maximum.
At present, be manual injection's insulin or orally-taken blood sugar reducing medicine to the primary treatment method of type ii diabetes both at home and abroad.Some medicines have significant hypoglycemic activity, but long-term taking also there will be adverse side effect (as glucinan or α glucosidase inhibitor).The blood-sugar decreasing active having no side effect is one of importance of functional food research and development.Type ii diabetes slower development, at early period of origination, due to compensatory insulin secretion, blood sugar maintains and normal physiologic values, hinders or postpone the diagnosis of the state of an illness.Meanwhile, can cause its exhaustion and degeneration to the chronic overstimulation of β cell, cause its insulin secretion ability to reduce gradually.The temporary transient dormancy of induction β cell can improve its insulin secretion ability, thereby delays the development of type ii diabetes.But, have apparent side effect at clinical practice insulin secretion inhibitor.Exploitation regulates the wholefood of insulin secretion extremely important.China's famous endocrine expert money is honourably obtained and is pointed out, High-risk Group of Diabetes should change ill so simple clinical concept of taking medicine, because diabetes are not to depend merely on to take medicine to treat the disease that just can deal with problems.Therefore, find and can be used for treating diabetes, the natural bioactivity substance of conditioning blood glucose balance or functional food are one of important hot issues of the outer treating diabetes research of Present Domestic.
Functional food refer to there is trophic function, the food of sensory function and adjusting physiological activity function, comprising: the food that strengthens human body constitution (strengthen immunocompetence, activate lymphatic system etc.); Prevent the food of disease (hypertension, diabetes, coronary heart disease, constipation and tumour etc.); The get well food of (control cholesterol, prevent platelet aggregation, regulate hematopoiesis function etc.); Regulate the food of the health rhythm and pace of moving things (nerve center, nerve ending, picked-up and absorption function etc.) and the food delaying senility.The research and development of functional food still belong to new branch of science and field in China, are products multidisciplinary, multi-field continuous mixing together, relate to nutrition, pharmacy, physiology, preventive medicine, bioengineering, Food Science.Therefore the functional food that, blood glucose balance is nursed one's health in development is safely and effectively significant to diabetes patient.
Summary of the invention
The present invention is intended to solve one of technical problem in prior art problem, for this reason, the invention provides a kind of functional food of nursing one's health blood glucose balance, include the pancreas islet adjustment factor, can play adjusting islet function, help insulin secretion in body to reach balance, thereby reach adjusting glycometabolism, the function of conditioning blood glucose balance.
In one aspect of the invention, the invention provides a kind of composition, mainly made by the raw material of following parts by weight: mulberry-leaf extract 30-50 part, cinnamomum cassia extract 30-50 part, vitamin C 5-10 part, vitamin E 5-10 part.
In addition, composition according to the above embodiment of the present invention can also have following additional technical characterictic:
In an embodiment of the present invention, composition of the present invention further comprises that the mixed raw material of following parts by weight becomes: 45 parts of mulberry-leaf extracts, 40 parts of cinnamomum cassia extracts, 10 parts of vitamin Cs, 5 parts of vitamin Es.
In an embodiment of the present invention, composition of the present invention further comprises that the mixed raw material of following parts by weight becomes: 45 parts of mulberry-leaf extracts, 45 parts of cinnamomum cassia extracts, 5 parts of vitamin Cs, 5 parts of vitamin Es.
In an embodiment of the present invention, composition of the present invention further comprises that the mixed raw material of following parts by weight becomes: 50 parts of mulberry-leaf extracts, 40 parts of cinnamomum cassia extracts, 5 parts of vitamin Cs, 5 parts of vitamin Es.
In embodiments of the invention, also provide a kind of preparation method of functional food, according to embodiments of the invention, its preparation method is as follows:
A. by mulberry-leaf extract 30-50 part, cinnamomum cassia extract 30-50 part, vitamin C 5-10 part, the powder raw material of vitamin E 5-10 part drops into respectively in mixer, stirs;
B. the powder raw material stirring is put into microwave dryer, dry and sterilizing;
C. the powder raw material of drying after also sterilizing is pulverized, sieved, obtain fine powder;
D. described fine powder material forming is made to functional food;
According to some embodiments of the present invention, in above-mentioned preparation method, the moisture of described powder raw material is 10%-20%.
According to some embodiments of the present invention, in above-mentioned preparation method, the thickness that described powder raw material is put into microwave dryer is 2-2.5cm.
According to some embodiments of the present invention, in above-mentioned preparation method, described powder raw material is dried and sterilising temp is 60-80 DEG C, and the time is 4-10 minute.
According to some embodiments of the present invention, in above-mentioned preparation method, described powder raw material is dried rear moisture and is less than 7%.
According to some embodiments of the present invention, in above-mentioned preparation method, described by dry and sterilizing after powder raw material pulverize, cross 100 mesh sieves.
According to some embodiments of the present invention, the functional food in the present invention is at least one form of capsule, tablet or electuary.
According to embodiments of the invention, pharmaceutical composition of the present invention can be for conditioning diabetes patient's blood glucose balance.
According to concrete examples more of the present invention, the present invention has set up a kind of tissue of experimental diabetic mice model, the functional food of conditioning blood glucose balance of the present invention has been carried out to functional experiment, find that a kind of functional food of nursing one's health blood glucose balance provided by the invention all has significant blood sugar reducing function to normal mouse and two kinds of diabetes models, meanwhile, the present invention has also carried out Oral toxicity test to a kind of functional food of nursing one's health blood glucose balance provided by the invention, the safety evaluatio experiment of binomial mutagenicity test (PCEMNR is counted micronucleus test and sperm malformation test) and 30 days feeding trials, test shows, press acute toxicity grading criteria evaluation, this given the test agent belongs to nontoxic level.
In the present invention, above-mentioned several raw material is except effect separately, it blends into one and forms after this food, through evidence, also have and can well regulate islet function, help insulin secretion in body to reach balance, regulate glycometabolism, also can reduce blood fat simultaneously, prevent blood vessel scleratheroma, can be good at adjusting the function that reaches conditioning blood glucose balance and prevention complication.Therefore, this food has the function of good conditioning blood glucose balance, can make user regulate blood sugar, reduces using and relying on, the toxic and side effect that minimizing medicine brings to health antidiabetic drug.On safe regulating and controlling blood sugar, this food be current safety effectively can be by regulating insulin secretion in islet function, dummy reach balance, reduce blood fat etc. and nurse one's health the healthy food of blood glucose balance.
It should be noted that, medical composition and its use of the present invention is that present inventor just completes through arduous creative work and Optimization Work.
Additional aspect of the present invention and advantage in the following description part provide, and part will become obviously from the following description, or recognize by practice of the present invention.
Detailed description of the invention
Describe embodiments of the invention below in detail.Embodiment described below is exemplary, only for explaining the present invention, and can not be interpreted as limitation of the present invention,
A kind of functional food of nursing one's health blood glucose balance provided by the invention, comprises that the mixed raw material of following parts by weight becomes:
Mulberry-leaf extract 30-50 part, cinnamomum cassia extract 30-50 part, vitamin C 5-10 part, vitamin E 5-10 part, these four kinds of raw materials are all bought from Jia Kang source, Beijing Chemical Co., Ltd..
Embodiment 1:
A kind of composition is provided, comprises that the mixed raw material of following parts by weight becomes: 45 parts of mulberry-leaf extracts, 40 parts of cinnamomum cassia extracts, 10 parts of vitamin Cs, 5 parts of powder raw materials of vitamin E.
Embodiment 2:
A kind of composition is provided, comprises that the mixed raw material of following parts by weight becomes: 45 parts of mulberry-leaf extracts, 45 parts of cinnamomum cassia extracts, 5 parts of vitamin Cs, 5 parts of powder raw materials of vitamin E.
Embodiment 3:
A kind of composition is provided, comprises that the mixed raw material of following parts by weight becomes: 50 parts of mulberry-leaf extracts, 40 parts of cinnamomum cassia extracts, 5 parts of vitamin Cs, 5 parts of powder raw materials of vitamin E.
Embodiment 4:
A kind of composition is provided, comprises that the mixed raw material of following parts by weight becomes: 30 parts of mulberry-leaf extracts, 50 parts of cinnamomum cassia extracts, 10 parts of vitamin Cs, 0 part of powder raw material of vitamin e1.
Preparation method: the preparation method who the invention provides a kind of food comprises stirring, oven dry and sterilizing, pulverizing and forming step, specific as follows:
Embodiment 5:
First will meet standard (quality standard in Q/WHF0003S-2012, as follows) 45 parts of mulberry-leaf extracts, 40 parts of cinnamomum cassia extracts, 10 parts of vitamin Cs, 5 parts of powder raw materials of vitamin E (parts by weight) drop in mixer, make it to stir, and to control raw material water content be 10～20%; The raw material mixing is laid in microwave dryer by the even thickness of 2～2.5cm again, under 60～80 DEG C of temperature, 4～10 minutes time condition, carries out sterilizing and oven dry, after drying, moisture is less than 7%; Then, by dry and sterilizing after powder raw material pulverize, sieve, while sieving, can use 100 orders, 80 orders or 60 mesh sieves, wherein preferred 100 mesh sieves, obtain fine powder; Finally, require fine powder raw material to make capsule according to functions of the state food technology, or tablet, or electuary, or other kind of packaging product.
Embodiment 6: first by 45 parts of standard compliant powder raw material (parts by weight) mulberry-leaf extracts, 45 parts of cinnamomum cassia extracts, 5 parts of vitamin Cs, in 5 parts of input mixers of vitamin E, make it to stir, and to control raw material water content be 10～20%; Following operation is with embodiment 5.
Embodiment 7: first by 50 parts of standard compliant powder raw material (parts by weight) mulberry-leaf extracts, 40 parts of cinnamomum cassia extracts, 5 parts of vitamin Cs, in 5 parts of input mixers of vitamin E, make it to stir, and to control raw material water content be 10～20%; Following operation is with embodiment 5.
Embodiment 8: first by 30 parts of standard compliant powder raw material (parts by weight) mulberry-leaf extracts, 50 parts of cinnamomum cassia extracts, 10 parts of vitamin Cs, in 0 part of input mixer of vitamin e1, make it to stir, and to control raw material water content be 10～20%; Following operation is with embodiment 5.
Functional experiment test:
The present inventor, by setting up tissue of experimental diabetic mice model, has carried out functional experiment test to composition of the present invention
Embodiment 9: the experiment test of effect of a kind of functional food provided by the invention
1. materials and methods
1.1 material
Sample: regulate blood glucose balance functional food by the one that in the above embodiment of the present invention 1 to 4, any one provides, provided by Kai Ze (Wuhan) health control Co., Ltd, human body recommended amounts is 30mg/ (dkg).
Animal used as test:
1. Kunming mouse, male, body weight 18～22g, is provided by Hubei Province's Experimental Animal Center, freely ingests, drinks water.The indoor 12h day-night cycle device that arranges of animal feeding, room temperature maintains (22 ± 2) DEG C.Feeds utilized is standard mouse feed, and energy density is 15.2kJ/g (energy percentage is respectively protein 23 .1%, fat 16.5%, carbohydrate 60.4%).
2.KKAy mouse, it is heredity diabetes animal model, show as type ii diabetes feature, male, body weight (30 ± 2) g, blood sugar screening criteria is 4h blood sugar >8.0mmol/L on an empty stomach, provided by Chinese Academy of Medical Sciences animal, feeding environment is the same, and feed is special high lipid food, and follower provides in the lump.
Experimental drug: alloxan, trade name: Alloxan, derives from Sigma company, lot number: 51kl132.
1.2 experimental technique
Tissue of experimental diabetic mice model is set up: get normal kunming mice, with PH=4-5, concentration is 0.5mol/L citric acid solution preparation alloxan solution, press 200mg/kg bw lumbar injection, destroy mice pancreatic B cell, inject and after 4 hours, give 10% glucose solution gavage, dead to avoid animal to faint from fear because lasting hypoglycemia causes, observe after 72 hours, measure the mouse empty stomach blood sugar of 4 hours, the animal of blood sugar >10mmol/L is for experiment.Animal pattern possesses type i diabetes feature.
1.3 experimental procedure
The experimental technique of the impact of a kind of functional food provided by the invention on normal mouse oral glucose tolerance (OGTT): get 24 of normal mouses, be divided at random experimental group and control group, 12 hours on an empty stomach, disposable through injection 1:3 give glucose 3g/kg bw, give a kind of functional food 1g/kg bw that regulates blood glucose balance according to preliminary experiment result experimental group is simultaneously disposable through injection 1:3,0.5h, 1h, 2h blood sugar after mensuration administration.
The experimental technique of a kind of functional food provided by the invention on the impact of I, type ii diabetes mouse blood sugar in random feed situation: each 20 of 2 kinds of diabetic mices, all be divided equally at random experimental group and control group, experimental group is disposable gives a kind of functional food 1g/kg bw that regulates blood glucose balance through injection 1:3, remove feed, 2h, 4h blood sugar after mensuration administration simultaneously.
The experimental technique of the impact of a kind of functional food provided by the invention on I, type ii diabetes mouse fasting blood-glucose: each 20 of 2 kinds of diabetic mices, all be divided equally at random experimental group and control group, animal fasting 4h before experiment, the disposable per os of experimental group gives CPS1g/kg bw, measures respectively 2h after administration, 4h blood sugar.Each experiment contrast group all gives isopyknic physiological saline above, and all the other operations are identical with experimental group.
1.4 observation index blood sugar detections are got animal tail vein glucose oxidase method, and instrument is Johnson & Johnson of U.S. Sure-Step blood glucose monitoring system and special test paper.
Statistical disposition relatively, represents with ± s between organizing with t inspection.
2 functional experiment results
2.1 a kind of functional foods that regulate blood glucose balance provided by the invention show the result that affects of normal mouse oral glucose tolerance (OGTT), a kind of functional food that regulates blood glucose balance provided by the invention can significantly improve normal mouse glucose tolerance, in table 1, experimental data demonstrates experimental group and is significantly less than control group, control group is 0.5h after glucose gavage, 1h blood sugar raises respectively 167% and 78%, and experimental group only raises 120% and 46%, two groups of comparison difference have significant (P<0.05), after administration 2h, two treated animal blood sugar reach quite level.
The impact of table 1 on normal glucose tolerance in mice
mmol/l
Note: with control group than P<0.05, P<0.01
In 2.2 random feed situations, a kind of functional food of blood glucose balance that regulates is on the impact of various blood glucose in diabetic mice
In table 2, the data of test demonstrate the impact of a kind of functional food provided by the invention on random feed type i diabetes mouse blood sugar, regulate the functional food of blood glucose balance to there is a remarkable reducing effect to random feed type i diabetes mouse blood sugar, and its hypoglycemic activity is gone back highly significant after administration after 4h.Control group 2h, 4h blood sugar after administration decline respectively 3% and 19%, and experimental group declines respectively 21% and 42%.
The effect of table 2 to random feed type 1 diabetes mouse blood sugar
mmol/L
Note: with control group than P<0.05, P<0.01
Table 3 demonstrates the impact of a kind of functional food provided by the invention on random feed diabetes B mouse blood sugar, control group 2h, 4h blood sugar after administration decline respectively 4% and 14%, experimental group blood sugar decline respectively 25% and 38%, two group of comparison difference there is significant.
The effect of table 3 to random feed diabetes B mouse blood sugar
mmol/L
Note: compare P<0.05 with control group
2.3 effects of a kind of functional food provided by the invention to various diabetic mice fasting blood-glucose
In table 4, data result shows, control group 2h, 4h blood sugar after administration decline respectively 11% and 31%, and experimental group blood sugar declines respectively 46% and 62%.After gavage, type i diabetes mouse fasting blood-glucose is had to remarkable reducing effect.
The impact of table 4 on type 1 diabetes mouse fasting blood-glucose
mmol/L
Note: with control group than P<0.05, P<0.01
Table 5 shows the effect of a kind of functional food provided by the invention to type ii diabetes mouse fasting blood-glucose, after gavage, can significantly reduce type ii diabetes mouse fasting blood-glucose.Control group 2h, 4h blood sugar after administration decline respectively 7% and 19%, experimental group blood sugar decline respectively 24% and 38%, two group of fall comparison difference there is significant.
The impact of table 5 on diabetes B mouse fasting blood-glucose
mmol/L
Note: compare P<O.05 with control group
In conjunction with above each experimental data, inventor draws to draw a conclusion, sugar tolerance experimental result to normal mouse in the present invention shows, it is disposable after 1:3 gives a kind of functional food 1g/kg bw provided by the invention, experimental group blood sugar level all significantly lower than control group, points out a kind of functional food provided by the invention to have the effect that reduces Postprandial peak glucose at 0.5h, 1h.While giving type i diabetes and type ii diabetes mouse a kind of functional food 1g/kg bw dosage provided by the invention, no matter be fasting blood-glucose or random blood sugar, there is significant decline, show that this food can reduce fasting blood-glucose and the random blood sugar of 2 kinds of diabetic mices.In a kind of functional food provided by the invention, there is multiple sugar-lowering components, except glucoside, also have alkaloid and a kind of similar insulinoid polypeptide compound, mainly contain para-insulin effect, stimulate B emiocytosis insulin and the effect of protection pancreas.
Safety assessment test
The present invention also provides a kind of assessment experiment, pass through acute toxicity test in mice, PCEMNR is counted micronucleus test, mouse sperm deformity test, 30 days feeding trials and the test of hematological examination result and animal pathologic diagnosis are evaluated the security performance of a kind of functional food provided by the invention.
Embodiment 10:
Acute toxicity test in mice
Test method:
To the SPF level Kunming mouse acute oral toxicity test of two kinds of sexes, method is with reference to the toxicology method of inspection of " health food inspection and assessment technique specification " 2003 editions, respectively 15 female mouse and 15 male mouse are carried out to gavage twice, each dosage is 20g/kg BW (be equivalent to crowd's recommended intake 0.03g/kg BW 667 times), through the observation period of 14 days, result of the test was in table 6.
One kind, table 6 regulates the functional food of blood glucose balance to acute toxicity test in mice result
Experimental data shows that two treated animals all do not observe Novel presentation, has no animal poisoning symptom and dead generation in two weeks.Press acute toxicity grading criteria evaluation, this given the test agent belongs to nontoxic level.
Embodiment 11:
PCEMNR is counted micronucleus test
SPF level Kunming mouse marrow polychromatic erythrocyte to two kinds of sexes is counted micronucleus test, and method, by the toxicology method of inspection of " health food inspection and assessment technique specification " 2003 editions, the results are shown in Table 7.
One kind, table 7 regulates the functional food of blood glucose balance to count micronucleus test result to PCEMNR
Note: with relatively * * P < 0.01 of negative control group
Experimental data shows, with negative control group comparison, positive controls male and female micronuclei in mice rate there were significant differences property (P < 0.01), and the each dosage group of given the test agent male and female micronuclei in mice rate and negative control group comparison, difference that there are no significant (P > 0.05), and all, in normal range (NR), show that this given the test agent bone marrow micronucleus test result is negative.
Embodiment 12:
Mouse sperm deformity test
To the sperm malformation test of SPF level Kunming mouse, method, by the toxicology method of inspection of " health food inspection and assessment technique specification " 2003 editions, the results are shown in Table 8.
One kind, table 8 regulates the functional food of blood glucose balance to mouse sperm deformity result of the test
Note: with relatively * * P < 0.01 of negative control group
Experimental data shows, with negative control group A comparison, positive controls mouse sperm deformity rate has significant difference (P < 0.01), and the each dosage group of given the test agent mouse sperm deformity rate and negative control group comparison, difference that there are no significant (P > 0.05), shows that this given the test agent sperm malformation test result is negative.
Embodiment 13:
30 days feeding trials
To 30 days feeding trials of SPF level Wistar rat of two kinds of sexes, method is by the toxicology method of inspection of " health food inspection and assessment technique specification " 2003 editions, and result is as follows: in process of the test, animal is without death, and hair is normal, shows without abnormal behaviour.
On the impact of rat body weight, food-intake, food utilization, the results are shown in Table 9-11.
One kind, table 9 regulates the functional food of blood glucose balance on the impact of rat body weight (mean ± standard deviation)
The impact (mean ± standard deviation) of the functional food that one kind, table 10 regulates blood glucose balance on rats eating amount
The impact (mean ± standard deviation) of the functional food that one kind, table 11 regulates blood glucose balance on rat food utilization
From table 9-11, there are no significant (P > 0.05) to rat body weight, food-intake, food utilization and negative control group comparing difference for the each dosage group of given the test agent.
Embodiment 14:
The test of hematological examination result
On the result that affects of rat serum routine inspection, on the result that affects of rat leukocyte classification, rat blood biochemical analysis affected to result respectively in table 12, table 13 and table 14.
The impact (mean ± standard deviation) of the functional food that one kind, table 12 regulates blood glucose balance on rat serum routine inspection result
Table 13 impact (mean ± standard deviation) that regulates the functional food of blood glucose balance to classify on rat leukocyte
The impact (mean ± standard deviation) of the functional food that one kind, table 14 regulates blood glucose balance on rat blood biochemical analysis
continued
In table 12, data show, the each dosage group of given the test agent and negative control group comparison, and difference that there are no significant (P > 0.05), and all in range of normal value.In table 13, data show, the each dosage group of given the test agent and negative control group comparison, and difference that there are no significant (P > 0.05), and all in range of normal value.In table 14, data show, measurement result and the negative control group comparison of the each dosage group of given the test agent rat blood serum alanine aminotransferase (ALT), glutamic-pyruvic transaminase (AST), blood urea nitrogen (BUN), CRE, glucose (GLU), TRI, CHO, ALB, TP, difference that there are no significant (P > 0.05), and all in range of normal value.
In conjunction with above each experimental data, inventor draws to draw a conclusion, and a kind of functional food that regulates blood sugar provided by the invention is a kind of food of safety non-toxic, can play the effect that regulates blood glucose balance, is again safety non-toxic to diabetes patient.
Although illustrated and described embodiments of the invention, those having ordinary skill in the art will appreciate that, in the situation that not departing from principle of the present invention and aim, can carry out multiple variation, amendment, replacement and modification to these embodiment, scope of the present invention is limited by claim and equivalent thereof.
Claims (10)
1. a functional food of nursing one's health blood glucose balance, is characterized in that, comprises mulberry-leaf extract, cinnamomum cassia extract, vitamin C, vitamin E.
2. the functional food of conditioning blood glucose balance according to claim 1, is characterized in that, comprises that the mixed raw material of following parts by weight becomes: mulberry-leaf extract 30-50 part, cinnamomum cassia extract 30-50 part, vitamin C 5-10 part, vitamin E 5-10 part.
3. the functional food of conditioning blood glucose balance according to claim 1 and 2, is characterized in that, described functional food is at least one form of capsule, tablet or electuary.
4. the functional food of conditioning blood glucose balance according to claim 1, is characterized in that, comprises that the mixed raw material of following parts by weight becomes:
Mulberry-leaf extract is 45 parts, and cinnamomum cassia extract is 40 parts, and vitamin C is 10 parts, and vitamin E is 5 parts.
5. the functional food of conditioning blood glucose balance according to claim 1, is characterized in that, comprises that the mixed raw material of following parts by weight becomes:
Mulberry-leaf extract is 45 parts, and cinnamomum cassia extract is 45 parts, and vitamin C is 5 parts, and vitamin E is 5 parts.
6. a preparation method who nurses one's health the functional food of blood glucose balance, is characterized in that, prepares through the following steps:
A. by mulberry-leaf extract 30-50 part, cinnamomum cassia extract 30-50 part, vitamin C 5-10 part, the powder raw material of vitamin E 5-10 part drops into respectively in mixer, stirs;
B. the powder raw material stirring is put into microwave dryer, dry and sterilizing;
C. the powder raw material of drying after also sterilizing is pulverized, sieved, obtain fine powder;
D. described fine powder moulding is made to functional food.
7. the preparation method of the functional food of conditioning blood glucose balance according to claim 6, is characterized in that, it is 2-2.5cm that powder raw material described in described b step is put into the thickness of microwave dryer.
8. the preparation method of the functional food of conditioning blood glucose balance according to claim 6, is characterized in that, in described b step, powder raw material oven dry sterilising temp are 60-80 DEG C, and the time is 4-10 minute.
9. the preparation method of the functional food of conditioning blood glucose balance according to claim 6, is characterized in that, powder raw material described in described b step is dried rear moisture and is less than 7%.
10. the preparation method of the functional food of conditioning blood glucose balance according to claim 6, is characterized in that, in described c step, the powder raw material after described oven dry sterilizing is pulverized, and crosses 100 mesh sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410320488.6A CN104082742B (en) | 2014-07-04 | 2014-07-04 | A kind of functional food nursing one's health blood glucose balance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410320488.6A CN104082742B (en) | 2014-07-04 | 2014-07-04 | A kind of functional food nursing one's health blood glucose balance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104082742A true CN104082742A (en) | 2014-10-08 |
| CN104082742B CN104082742B (en) | 2016-06-29 |
Family
ID=51630590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410320488.6A Active CN104082742B (en) | 2014-07-04 | 2014-07-04 | A kind of functional food nursing one's health blood glucose balance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104082742B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106723021A (en) * | 2016-11-28 | 2017-05-31 | 武汉哈福科技有限公司 | A kind of functional food for improving the health care of sleep |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0930019A2 (en) * | 1997-12-25 | 1999-07-21 | Lotte Co., Ltd | Composition for treating obesity and foods and drinks containing the same |
| CN1792247A (en) * | 2005-12-27 | 2006-06-28 | 武汉哈福科技有限公司 | Health-care food with functions of anti-senium and cosmetic |
| CN102273621A (en) * | 2010-06-09 | 2011-12-14 | 苏州润新生物科技有限公司 | Food or health-care food for preventing and treating diabetes mellitus |
| CN102511712A (en) * | 2011-12-19 | 2012-06-27 | 苏州先阔生物科技有限公司 | Xylo-oligosaccharide-containing healthcare food auxiliary for blood sugar reduction |
| CN102727706A (en) * | 2011-04-02 | 2012-10-17 | 苏州润新生物科技有限公司 | Composition for preventing and treating diabetes |
| CN102727586A (en) * | 2011-04-02 | 2012-10-17 | 苏州润新生物科技有限公司 | Composition for preventing and treating diabetes |
-
2014
- 2014-07-04 CN CN201410320488.6A patent/CN104082742B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0930019A2 (en) * | 1997-12-25 | 1999-07-21 | Lotte Co., Ltd | Composition for treating obesity and foods and drinks containing the same |
| CN1792247A (en) * | 2005-12-27 | 2006-06-28 | 武汉哈福科技有限公司 | Health-care food with functions of anti-senium and cosmetic |
| CN102273621A (en) * | 2010-06-09 | 2011-12-14 | 苏州润新生物科技有限公司 | Food or health-care food for preventing and treating diabetes mellitus |
| CN102727706A (en) * | 2011-04-02 | 2012-10-17 | 苏州润新生物科技有限公司 | Composition for preventing and treating diabetes |
| CN102727586A (en) * | 2011-04-02 | 2012-10-17 | 苏州润新生物科技有限公司 | Composition for preventing and treating diabetes |
| CN102511712A (en) * | 2011-12-19 | 2012-06-27 | 苏州先阔生物科技有限公司 | Xylo-oligosaccharide-containing healthcare food auxiliary for blood sugar reduction |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106723021A (en) * | 2016-11-28 | 2017-05-31 | 武汉哈福科技有限公司 | A kind of functional food for improving the health care of sleep |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104082742B (en) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104026446B (en) | A kind of it is suitable for nutritional meal replacement powder that hyperglycemia population takes and preparation method thereof | |
| CN106360310A (en) | Composition for dropping after meal blood sugar and application thereof | |
| CN102406860A (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
| CN101878906B (en) | Health care food with auxiliary hyperglycemic function and preparation method thereof | |
| CN102551065B (en) | Blood sugar reducing food series | |
| CN105596646A (en) | Medicine, health-care product or food composition for controlling blood glucose and treating abnormal blood lipid metabolism | |
| CN105079089A (en) | Preparation method of kudzuvine root and bitter gourd health-care food assisting in reducing blood glucose | |
| CN106723021A (en) | A kind of functional food for improving the health care of sleep | |
| CN104857088A (en) | Preparation method of mulberry leaf compound capsule for lowering blood glucose in assistant manner | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN104095234B (en) | A kind of functional food nursing one's health fatty liver | |
| CN105265985B (en) | A kind of corn stigma solid beverage and preparation method thereof | |
| CN102847159A (en) | A glucose metabolism enhancer | |
| CN105725187A (en) | Blood sugar reducing composition and application in preparation of foods and health-care foods | |
| CN1706281A (en) | Health food with subsidiary function of lowering blood sugar and lowering blood fat and its production process | |
| CN104082742B (en) | A kind of functional food nursing one's health blood glucose balance | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN105410941A (en) | Serene Tablet health-care food capable of increasing bone density and strengthening immunity and preparation method thereof | |
| CN100531783C (en) | Health-care food for reducing blood sugar on the assistant role and its preparing process | |
| CN102578451A (en) | Health-care food composite capable of decreasing blood sugar | |
| CN107050090A (en) | The effect of beneficial liver and its application of high mountain horseradish dish | |
| CN104173734B (en) | A kind of pharmaceutical composition for treating IGR and preparation method thereof | |
| WO2018072276A1 (en) | Health-care food and preparation method therefor | |
| CN104127816B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN104256576A (en) | Functional food capable of regulating blood pressure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170105 Address after: 430000 Hubei Province, Wuhan East Lake Development Zone high-tech road No. 666 Wuhan national biological industry base project B, C, D & B1 building area Patentee after: Wuhan Hava Bioscience Co., Ltd. Address before: 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666 Wuhan city industrial base project B, C, D, B1 block Patentee before: Keyser (Wuhan) Health Management Co., Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 430075, Hubei, East Lake Province Development Zone, 666 high-tech Avenue, Wuhan city industrial base project B, C and D District B1 building, Wuhan Patentee after: HAFU TECHNOLOGY (WUHAN) GROUP Co.,Ltd. Address before: 430000, Hubei, East Lake Development Zone, 666 hi tech Avenue, Wuhan National Bio industrial base project B, C and D District R & D building B1 building, Wuhan Patentee before: WUHAN HAVA BIOSCIENCE Co.,Ltd. |